Co-Diagnostics, Inc.
NASDAQRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Co-Diagnostics, Inc. (NASDAQ: CODX) develops, manufactures, and markets molecular diagnostics technologies utilizing nucleic acid detection and analysis (DNA or RNA); its proprietary Co-Primers technology enables multiplex PCR testing with innovations in color chemistry and melting analysis for infectious diseases, genetic markers, and other applications. The company offers a portfolio of real-time PCR reagents and tests including Logix Smart COVID-19 (RUO), Logix Smart Monkeypox (RUO), Logix Smart Mpox (2-Gene) (RUO), Logix Smart SARS-CoV-2 (Genes RdRp/E) (RUO), Logix Smart ABC (RUO), STD Panel, HCV RNA Real-time PCR Kit, HIV RNA Real-time PCR Kit, Tuberculosis (TB), Zika, hepatitis B and C, Malaria, dengue, EIKON PCR, LightPCR, Liquid Biopsy Test for cancer screening, and ABC Test; it also provides the Co-Dx PCR platform comprising the Co-Dx PCR Pro instrument, diagnostic test cup system, MDx device, lab systems, point-of-care and at-home devices like Co-Dx PCR Home and Co-Dx Box, and associated mobile applications for rapid results in approximately 30 minutes. Founded in 2013 and headquartered in Salt Lake City, Utah, with an address at 2401 S Foothill Dr Suite D, the company targets healthcare providers, diagnostic labs, consumers, point-of-care facilities, food safety sectors, and international markets through operations focused on democratizing accessible, low-cost molecular testing globally. In recent developments, Co-Diagnostics established Comira Diagnostics as a joint venture with Arabian Eagle Manufacturing to localize and distribute diagnostics in Saudi Arabia and 18 additional MENA countries; formed Kocera Diagnostics as its Indian joint venture, engaging Maxim Group LLC as exclusive financial advisor to explore strategic alternatives including a potential SPAC transaction; and received an NIH RadixTech grant to advance diagnostic innovations.
Co-Diagnostics Appoints Wes Lindsey, PhD, MBA as Chief Scientific Officer
Co-Diagnostics Invited to Participate in NPOC Tuberculosis Diagnostics Workshop in Bangkok, Thailand
Co-Diagnostics Completes Clinical and Analytical Studies in Preparation for FDA 510(k) Submission of Upper Respiratory Point-of-Care Test
Co-Diagnostics Vector Smart® Division Expands Footprint to 21 States
Co-Diagnostics Advances Latin American Commercialization Strategy for Co-Dx™ PCR Pro® with Mexico Distributor Agreement
Co-Diagnostics and CoSara Advance Ebola PCR Test Development and Co-Dx™ PCR Point-of-Care Platform Capabilities
Is Co-Diagnostics National Security's Next Diagnostic Pick?
Co-Diagnostics Advances Ebola PCR Assay Development Strategy with Joint Venture CoSara
Co-Diagnostics Announces $3.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Co-Diagnostics Develops Ebola Assay Strategy Following Recent Global Outbreak Alert
Co-Diagnostics, Inc. (CODX) Q1 2026 Earnings Call Transcript
Co-Diagnostics Reports First Quarter 2026 Financial Results
Co-Diagnostics Joint Venture CoMira Finalizes Lease Agreement for Manufacturing Facility in Saudi Arabia's Sudair Industrial City
Co-Diagnostics Announces First Quarter 2026 Earnings Release Date and Webcast
Co-Diagnostics Invited to Present at Stop TB Partnership Summit in Washington, D.C.
Co-Diagnostics to Showcase Co-Dx PCR Platform and CE-IVD Solutions at ESCMID 2026 in Munich, Germany
Co-Diagnostics Executives to Participate in European Trade Mission with Utah Governor and WTC Utah
Co-Diagnostics, Inc. (CODX) Q4 2025 Earnings Call Transcript
Co-Diagnostics Reports Full Year 2025 Financial Results
Co-Diagnostics Ships Diagnostic Materials to India for Initiation of Tuberculosis Clinical Studies Following Recently Issued Guidance from the World Health Organization